First in Taiwan in Asia, Jianqiao’s new generation oral drug is approved for new indications for endometriosis

Lin Zhihui, Chairman of Jianqiao.

[Reporter Chen Yongji/Taipei Report] Domestic pharmaceutical company Jianqiao Xinyuan (4114) and Japanese partner Kissei jointly announced today the new generation of oral gonadotropin-releasing hormone (GnRH) antagonist "Yselty" film-coated tablets 100 "MG" has been approved by the Ministry of Health and Welfare as a new indication for endometriosis, and is suitable for the treatment of pain symptoms caused by endometriosis in adult women of childbearing age who have received medical or surgical treatment. Jianqiao said that Taiwan is the first market in Asia to approve the use of Asti® for endometriosis, bringing a new oral treatment option to domestic patients.

Jianqiao stated that Jusheng Pharmaceuticals granted Jianqiao Xinyuan the right to develop and sell Yselty® in Taiwan in November 2022, and obtained Taiwan's marketing authorization in October 2025. The original approved indication was the treatment of excessive menstrual bleeding caused by uterine fibroids in adult women of childbearing age. In December of the same year An application was submitted for a new indication for endometriosis, and it will be launched in Taiwan in March 2026 as an indication for uterine fibroids. It has been introduced by 174 medical institutions, covering 12 medical centers. The approval of this new indication further expands Jianqiao's treatment layout in the field of women's health.

Jian Qiao pointed out that endometriosis is a common chronic gynecological disease among women of childbearing age. Patients may suffer from dysmenorrhea, pelvic pain and sexual intercourse pain, and some patients may also face infertility. This new indication provides another oral treatment option for patients who have undergone medical or surgical treatment and are still suffering from pain.